Relay Therapeutics (RLAY) Total Liabilities (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Total Liabilities of $57.4 million for Q1 2026, down 26.64% year-over-year from $78.3 million in Q1 2025, and up 5.82% quarter-over-quarter from $54.3 million in Q4 2025.
Relay Therapeutics (RLAY) Total Liabilities (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Total Liabilities for 8 consecutive years, with $57.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 26.64% year-over-year to $57.4 million; the TTM figure through Mar 2026 stood at $57.4 million (down 26.64% YoY), while the FY2025 annual figure was $54.3 million, down 41.96% from the prior year.
- Total Liabilities rose to $57.4 million in Q1 2026 per RLAY's latest filing, from $54.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $168.9 million in Q3 2022 and bottomed at $54.3 million in Q4 2025.
- Historically, Total Liabilities has averaged $102.9 million across 5 years, with a median of $93.5 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 179.84% — and 2025, when it slumped 41.96%.
- Relay Therapeutics' Total Liabilities stood at $149.6 million in 2022, then slumped by 38.5% to $92.0 million in 2023, then climbed by 1.66% to $93.5 million in 2024, then plunged by 41.96% to $54.3 million in 2025, then climbed by 5.82% to $57.4 million in 2026.
- Business Quant data shows RLAY's Total Liabilities at $57.4 million in Q1 2026, $54.3 million in Q4 2025, and $62.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 77.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.45 Mn |
| Mar 31, 2026 | 57.43 Mn |
| Dec 31, 2025 | 54.27 Mn |
| Sep 30, 2025 | 62.29 Mn |
| Jun 30, 2025 | 63.18 Mn |
| Mar 31, 2025 | 78.28 Mn |
| Dec 31, 2024 | 93.50 Mn |
| Sep 30, 2024 | 91.25 Mn |
| Jun 30, 2024 | 90.81 Mn |
| Mar 31, 2024 | 95.68 Mn |
| Dec 31, 2023 | 91.98 Mn |
| Sep 30, 2023 | 128.59 Mn |
| Jun 30, 2023 | 151.90 Mn |
| Mar 31, 2023 | 154.15 Mn |
| Dec 31, 2022 | 149.55 Mn |
| Sep 30, 2022 | 168.95 Mn |
| Jun 30, 2022 | 109.78 Mn |
| Mar 31, 2022 | 107.91 Mn |
| Dec 31, 2021 | 110.64 Mn |
| Sep 30, 2021 | 100.53 Mn |